June 27, 2008 Journal article Open Access

Trumbo PhD, Paula R.; Ellwood, Kathleen C.

JSON-LD (schema.org) Export

{
  "description": "The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.", 
  "license": "https://creativecommons.org/publicdomain/zero/1.0/legalcode", 
  "creator": [
    {
      "@type": "Person", 
      "name": "Trumbo PhD, Paula R."
    }, 
    {
      "@type": "Person", 
      "name": "Ellwood, Kathleen C."
    }
  ], 
  "headline": "Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence\u2010Based Review by the United States Food and Drug Administration", 
  "image": "https://zenodo.org/static/img/logos/zenodo-gradient-round.svg", 
  "datePublished": "2008-06-27", 
  "url": "https://zenodo.org/record/1230786", 
  "@context": "https://schema.org/", 
  "identifier": "https://doi.org/10.1111/j.1753-4887.2006.tb00220.x", 
  "@id": "https://doi.org/10.1111/j.1753-4887.2006.tb00220.x", 
  "@type": "ScholarlyArticle", 
  "name": "Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence\u2010Based Review by the United States Food and Drug Administration"
}